You are here: Industry Insights > Harmony Biosciences

News List

Harmony Biosciences Enrolls First Patient in Pitolisant Trial for Excessive Daytime Sleepiness americanpharmaceuticalreview
December 17, 2020
Harmony Biosciences announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome.
Harmony Biosciences Receives FDA Approval for Expanded Use of WAKIX americanpharmaceuticalreview
October 21, 2020
Harmony Biosciences announced the U.S. Food and Drug Administration (FDA) has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy.
Harmony Biosciences Announces FDA Approval of WAKIX americanpharmaceuticalreview
August 16, 2019
Harmony Biosciences announced the U.S. Food and Drug Administration (FDA) approved WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.